GlassScriptPhysician profile
Megan Powers
NPI 1598216830
$907.72
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $367 · 2022: $292 · 2023: $117 · 2024: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $225.82 | 2021-2024 | Breztri |
| Lilly USA, LLC | $209.47 | 2021-2023 | Mounjaro, Trulicity |
| Abbvie INC. | $87.54 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $86.80 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.79 | 2021 | |
| Novo Nordisk INC | $41.31 | 2022-2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $39.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.47 | 2021 | |
| Organon LLC | $33.88 | 2021-2022 | |
| Exact Sciences Corporation | $33.79 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $15.21 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.45 | 2021 | |
| Dexcom, INC. | $13.33 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.